Subtype
Pancreatic Neoplasm
CI-CAN-00001356Explore in graph →
Non-malignant988 active trials8 approved drugs63 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001356Explore in graph →
Clinical trials
4,217 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05369312 | Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients | unknown | Phase 1 | 230 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 21, 2022 | clinicaltrials |
| NCT03666832 | Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-Paclitaxel(MP-PDAC-01) | unknown | Phase 1 / Phase 2 | 36 | Joon Oh ParkOTHER |
| 1 |
| Jun 15, 2022 |
| clinicaltrials |
| NCT04258072 | Vactosertib With Nal-IRI/FL in Metastatic Pancreatic Ductal Adenocarcinoma. | unknown | Phase 1 | 24 | Samsung Medical CenterOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT02451553 | Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer | completed | Phase 1 | 41 | University of WashingtonOTHER | 1 | Jun 7, 2022 | clinicaltrials |
| NCT02514031 | ARQ-761 Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Pancreatic Cancer | terminated | Phase 1 | 17 | University of Texas Southwestern Medical CenterOTHER | 1 | Jun 3, 2022 | clinicaltrials |
| NCT01918644 | Neoadjuvant SBRT With Concomitant Capecitabine in Resectable Pancreatic Cancer | completed | Phase 1 | 21 | University of Wisconsin, MadisonOTHER | 1 | Jun 1, 2022 | clinicaltrials |
| NCT03412799 | Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer | completed | Phase 1 | 50 | Panbela Therapeutics, Inc.INDUSTRY | 2 | May 25, 2022 | clinicaltrials |
| NCT04327986 | Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | May 18, 2022 | clinicaltrials |
| NCT04131192 | Gemcitabine and Z650 in Treating Patients With Metastatic or Recurrent Pancreatic Cancer | terminated | Phase 1 | 13 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | May 6, 2022 | clinicaltrials |
| NCT02702986 | Safety and Feasibility of imILT Locally Advanced Pancreatic Cancer (LAPC) | completed | Phase 1 | 10 | Universita di VeronaOTHER | 1 | Apr 21, 2022 | clinicaltrials |
| NCT01198522 | Combination Therapy of L19IL2 and Gemcitabine in Advanced Pancreatic Cancer Patients | terminated | Phase 1 | 28 | Philogen S.p.A.INDUSTRY | 2 | Apr 15, 2022 | clinicaltrials |
| NCT05327582 | An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC | unknown | Phase 1 / Phase 2 | 65 | Chinese PLA General HospitalOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT03162510 | Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers(SOLAR) | completed | Phase 1 | 18 | National Health Research Institutes, TaiwanOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT03147768 | Laser Tissue Welding - Distal Pancreatectomy Sealing Study(LTW) | completed | Phase 1 | 11 | Laser Tissue Welding, Inc.INDUSTRY | 1 | Apr 6, 2022 | clinicaltrials |
| NCT03682744 | CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC) | withdrawn | Phase 1 | 0 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Apr 6, 2022 | clinicaltrials |
| NCT02646748 | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | completed | Phase 1 | 159 | Incyte CorporationINDUSTRY | 1 | Mar 31, 2022 | clinicaltrials |
| NCT03300921 | A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer | terminated | Phase 1 | 3 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT02810418 | Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors | completed | Phase 1 / Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Mar 15, 2022 | clinicaltrials |
| NCT02526017 | Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers(FPA008-003) | completed | Phase 1 | 313 | Five Prime Therapeutics, Inc.INDUSTRY | 1 | Mar 9, 2022 | clinicaltrials |
| NCT05162118 | Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 51 | Zhejiang UniversityOTHER | 1 | Mar 9, 2022 | clinicaltrials |
| NCT00447122 | BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer | terminated | Phase 1 | 25 | Brown UniversityOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT03281382 | Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic Cancer | completed | Phase 1 | 12 | Henry Ford Health SystemOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT03985072 | Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor | completed | Phase 1 | 67 | Andes BiotechnologiesINDUSTRY | 1 | Feb 24, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT05240690 | Umbilical Cord Blood Derived MAK Immune Cells Combined With Standard Second-Line Treatments for Hepatobiliary and Pancreatic Malignancies | unknown | Phase 1 | 27 | Zhou FuxiangOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT00617708 | S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery | completed | Phase 1 / Phase 2 | 134 | National Cancer Institute (NCI)NIH | 1 | Feb 8, 2022 | clinicaltrials |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | terminated | Phase 1 | 67 | MacroGenicsINDUSTRY | 3 | Feb 8, 2022 | clinicaltrials |
| NCT05181865 | Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Flame BiosciencesINDUSTRY | 0 | Feb 7, 2022 | clinicaltrials |
| NCT00967577 | 177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors | completed | Phase 1 | 20 | Weill Medical College of Cornell UniversityOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT02947165 | Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. | completed | Phase 1 | 120 | Novartis PharmaceuticalsINDUSTRY | 9 | Jan 31, 2022 | clinicaltrials |
| NCT03637491 | A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors | terminated | Phase 1 / Phase 2 | 36 | PfizerINDUSTRY | 3 | Jan 26, 2022 | clinicaltrials |
| NCT04652206 | Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.(PANTAX-Ib) | unknown | Phase 1 / Phase 2 | 18 | Scandion Oncology A/SINDUSTRY | 2 | Dec 29, 2021 | clinicaltrials |
| NCT05172310 | PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI | recruiting | Phase 1 | 410 | Karolinska University HospitalOTHER | 1 | Dec 29, 2021 | clinicaltrials |
| NCT04191928 | Pharmacokinetics of Apixaban in Patients Undergoing Pancreaticoduodenectomy(PAP-UP) | completed | Phase 1 | 4 | Thomas Jefferson UniversityOTHER | 1 | Dec 23, 2021 | clinicaltrials |
| NCT04105062 | LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric Surgery | withdrawn | Phase 1 / Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Dec 9, 2021 | clinicaltrials |
| NCT05143151 | CD276-targeted Chimeric Antigen Receptor T Cells in Treatment With Advanced Pancreatic Cancer(CAR-T) | unknown | Phase 1 / Phase 2 | 10 | Shenzhen University General HospitalOTHER | 1 | Dec 3, 2021 | clinicaltrials |
| NCT03319459 | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | completed | Phase 1 | 44 | Fate TherapeuticsINDUSTRY | 1 | Nov 22, 2021 | clinicaltrials |
| NCT03645148 | Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Pancreatic Cancer | completed | Phase 1 | 7 | Zhejiang Provincial People's HospitalOTHER | 1 | Nov 16, 2021 | clinicaltrials |
| NCT04810910 | Personalized Neoantigen Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy | unknown | Phase 1 | 20 | Zhejiang Provincial People's HospitalOTHER | 1 | Nov 16, 2021 | clinicaltrials |
| NCT05009966 | Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor | unknown | Phase 1 | 272 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Oct 25, 2021 | clinicaltrials |
| NCT01523808 | Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase)in Patients With Pancreatic Cancer | completed | Phase 1 | 12 | ERYtech PharmaINDUSTRY | 0 | Oct 15, 2021 | clinicaltrials |
| NCT02308722 | SBRT Pre-operatively for Pancreatic Cancer(SPARC) | completed | Phase 1 | 12 | University of OxfordOTHER | 1 | Oct 7, 2021 | clinicaltrials |
| NCT02777710 | Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers(MEDIPLEX) | completed | Phase 1 | 48 | Centre Leon BerardOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT02687230 | Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1 | terminated | Phase 1 | 15 | BioNTech Research & Development, Inc.INDUSTRY | 1 | Aug 31, 2021 | clinicaltrials |
| NCT04928625 | A Trial of SHR-A1904 in Patients With Advanced Pancreatic Cancer | unknown | Phase 1 | 75 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 24, 2021 | clinicaltrials |
| NCT00041639 | Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer | completed | Phase 1 / Phase 2 | 75 | Gilead SciencesINDUSTRY | 4 | Aug 19, 2021 | clinicaltrials |
| NCT00597129 | Safety and Efficacy Study of 90Y-hPAM4 at Different Doses | completed | Phase 1 / Phase 2 | 21 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT01510561 | A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies. | withdrawn | Phase 1 | 0 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT02138383 | Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer | completed | Phase 1 | 25 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 17, 2021 | clinicaltrials |
| NCT00603863 | Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer | completed | Phase 1 / Phase 2 | 80 | Gilead SciencesINDUSTRY | 1 | Aug 16, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Jun 21, 2022source: clinicaltrials